Jarden valuation, page-13

Just a friendly reminder of how distressed the Telix balance sheet is, this is from the September quarterly.

cash reserves of $45.55m
cash runway reported in 4C: 5.8 quarters (so notionally until some time in 2023)
"Telix considers that the company has 4 quarters of runway"

I know I'm repeating myself here, but: of course it's possible they'll raise, never say never. But I would guess they'll wait until next year. My reasoning is:

- they hope/ expect to have FDA approval by then
- they hope/ expect to have a positive ZIRCON trial resuly by then
- the PROSTACT trial should be running in the US by then. This is a large trial (~400 patients) which gives them the pretext for saying "we need the money".

The FDA decision is something like 8 weeks away. The company has far more than 8 weeks cash in hand. I'll wait until the FDA decision before I start worrying about the company strategy for money.